**M3 Literature Review**

**Period: 08/03/2025 – 08/04/2025**

[Scientific Highlights: 1](#_Toc143520007)

[Clostridioides difficile/ Clostridium difficile 3](#_Toc143520008)

[Fidaxomicin & Clostridium difficile 4](#_Toc143520009)

[Clostridioides difficile vaccine 4](#_Toc143520010)

[Vancomycin & CDI 4](#_Toc143520011)

[CDI 4](#_Toc143520012)

[FMT/ Fecal Microbiota Transplant 5](#_Toc143520013)

[Competitors 5](#_Toc143520014)

[CDAD 6](#_Toc143520015)

[CMC 6](#_Toc143520016)

[Guidelines 6](#_Toc143520017)

[Non-toxigenic C. difficile 6](#_Toc143520018)

[MGB 6](#_Toc143520019)

[Other news of possible interest 7](#_Toc143520020)

Scientific Highlights:

1. Secondary SBP Prophylaxis is associated with a higher rate of non-SBP infections in Two US-based National Cirrhosis Cohorts.
2. Anatomic Drivers of J-Sign Presence and Severity: If There Is a Jump, Look for a Bump.
3. Efficacy and safety of early antibiotic de-escalation in febrile neutropenia for patients with hematologic malignancy: a systematic review and meta-analysis.
4. Thrombosis Secondary to Intravenous Dicyclomine Administration: A Case Report and Literature Review.
5. Fecal microbiota transplantation in a patient hospitalized in the intensive care unit - Case report.
6. Impact of Clostridioides difficile Infection on Clinical Outcomes in Hospitalized IBD Patients and the Role of Fecal Microbiota Transplantation: A Retrospective Cohort Study.
7. Risk Factors for Antibiotic Exposure Post-Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection: A Prospective Multicenter Observational Study.
8. Molecular clock complexities of Clostridioides difficile.
9. A "movement" worth making: why and how Transfusion Services can play a role in Fecal Microbiota Transplant programs.
10. Characteristics and Real-World Outcomes of Patients Treated with Fecal Microbiota, Live-jslm (RBL) for the Prevention of Recurrent Clostridioides difficile Infection.
11. Australian Paediatric Surveillance Unit (APSU) Annual Surveillance Report 2023.
12. Repurposing thioridazine as a potential CD2068 inhibitor to mitigate antibiotic resistance in Clostridioides difficile infection.
13. [Challenges and progress in in the clinical application of fecal microbiota transplantation].
14. Clostridium Butyricum Miyairi Bacteriocin Treatment for Clostridioides difficile Infections with Clinical Isolates: Insights from In Vitro, Ex Vivo, and Mouse Model Studies.
15. Impact of Fecal Microbiota Transplant Formulations, Storage Conditions, and Duration on Bacterial Viability, Functionality, and Clinical Outcomes in Patients with Recurrent Clostridioides difficile Infection.
16. Exploring the Immunological Role of the Microbial Composition of the Appendix and the Associated Risks of Appendectomies.
17. Insights into the Interaction Between Clostridioides difficile and the Gut Microbiome.
18. Microbiota transplantation and administration of live biotherapeutic products for the treatment of dysbiosis-associated diseases.
19. Evaluating Bezlotoxumab-Fidaxomicin Combination Therapy in Clostridioides Infection: A Single-Center Retrospective Study from Aichi Prefecture, Japan.
20. Fecal microbiota transplantation to decolonize vancomycin-resistant Enterococcus: A pilot study to evaluate safety and clinical outcome.
21. [Clostridioides difficile infections at Landspítali University Hospital 2017-2022].
22. Outcomes of Fecal Microbiota Transplantation for Clostridioides difficile Infection in South Australia.
23. Safety and Efficacy of Fecal Microbiota, Live-jslm, in Preventing Recurrent Clostridioides difficile Infection in Participants Who Were Mildly to Moderately Immunocompromised in the Phase 3 PUNCH CD3-OLS Study.
24. Analysis of Multiple Programmed Cell Death Patterns and Functional Validations of Apoptosis-Associated Genes in Lung Adenocarcinoma.
25. Fidaxomicin for Clostridioides difficile infection in patients with inflammatory bowel disease: a multicentre retrospective cohort study.
26. In vitro susceptibility of clinical Clostridioides difficile isolates in Israel to metronidazole, vancomycin, fidaxomicin, ridinilazole and ibezapolstat.
27. Avoiding Premature Antibiotic Use in Recurrent Clostridioides difficile Infection After Fecal Microbiota Transplant.
28. Health economic burden of refractory and recurrent Clostridioides difficile infection in the inpatient setting of the German health care system - the IBIS Study.
29. Assessment of Dientamoeba fragilis interhuman transmission by fecal microbiota transplantation.
30. Colitis in Multiple Sclerosis Patients Treated with B-cell Depleting Monoclonal Antibodies (P8-1.014).
31. Treatment of Clostridioides difficile: The Times They are a Changing.

Clostridioides difficile/ Clostridium difficile

1. INFECTIOUS ENTEROCOLITIS IN HEMATOPOIETIC CELL TRANSPLANT WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE.
2. A mixed-methods study assessing the performance of a clinical decision support tool for Clostridioides difficile testing for patients receiving laxatives.
3. Three stages of laboratory stewardship in improving appropriate Clostridioides difficile testing in a community-based setting.
4. Evaluation of Nutrition Therapy in Critically Ill Patients with Clostridioides difficile Infection.
5. Evaluation of a Fluorescence Immunoassay for Detection of Clostridioides difficile Glutamate Dehydrogenase and Toxin Antigens.
6. Molecular detection of toxigenic Clostridioides difficile in subgingival biofilm of severe periodontitis.
7. Association Between Reporting Antimicrobial Use and Clostridioides difficile Standardized Infection Ratios in South Carolina Hospitals.
8. Antibiotic Usage and Healthcare-Associated Clostridioides difficile in Patients with and Without COVID-19: A Tertiary Hospital Experience.
9. Comparison of Medicare claims-based Clostridioides difficile infection epidemiologic case classification algorithms to medical record review by the Emerging Infections Program using a linked cohort, 2016-2021.
10. Determination of the performance of a novel diagnostic test for Clostridioides difficile toxins A and B using latent class analysis.
11. Surveillance of MRSA, ESBL-producing Klebsiella pneumoniae, carbapenem-resistant Enterobacteriaceae, and Clostridioides difficile in Catalan Hospitals: Findings from the VINCat Program.

Fidaxomicin & Clostridium difficile

1. Fecal Microbiota Transplantation for Refractory Clostridioides difficile Infection Post Haploidentical Transplant for Pediatric Acute Myeloid Leukemia.
2. Precision microbiota therapy for IBD: premise and promise.

Clostridioides difficile vaccine

1. Evaluation of Indigenous status completeness in vaccine preventable disease notification data in the NNDSS.
2. Vaccinating against Clostridioides difficile Infection.

Vancomycin & CDI

1. Comparative effectiveness of metronidazole and vancomycin for treatment of Clostridioides difficile infection in hospitalized children.
2. Efficacy of antimicrobials in preventing resistance in solid organ transplant recipients: A systematic review of clinical trials.
3. Prophylactic Vancomycin in the Primary Prevention of Clostridium difficile in Allogeneic Stem Cell Transplant.
4. Comprehensive review of Clostridium difficile infection: Epidemiology, diagnosis, prevention, and treatment.
5. Demographic characteristics and clinical and laboratory features of patients with Clostridiodes difficile infection: A retrospective study in Qatar.
6. From Escar to Diagnosis: A Case Report on Scrub Typhus causing multiorgan failure in a Returning Traveler.

CDI

FMT/ Fecal Microbiota Transplant

1. Fecal Microbiota Transplantation for Refractory Clostridioides difficile Infection Post Haploidentical Transplant for Pediatric Acute Myeloid Leukemia.
2. Precision microbiota therapy for IBD: premise and promise.

Competitors

1. Clinical frailty predicts long-term survival and return to functional status following fenestrated and branched aortic repair for thoracoabdominal aortic aneurysm.
2. Impact of tebipenem pivoxil on the intestinal microbiota and on establishment of colonization with carbapenem-resistant Klebsiella pneumoniae in mice.
3. Factors Influencing the Intentions of Patients With Inflammatory Rheumatic Diseases to Use a Digital Human for Medication Information: Qualitative Study.
4. The Safety and Efficacy of Microbial Ecosystem Therapeutic-2 in People With Major Depression - A Phase 2, Double-Blind, Placebo-Controlled Study: Clinical Results: Innocuité et efficacité du traitement de l'écosystème microbien (met-2) dans la dépression majeure - une étude de phase 2 à double insu contrölée par placebo : résultats cliniques.
5. Repurposing drugs to advance the treatment of Buruli ulcer.
6. A systematic review of noninvasive laboratory indices and elastography to predict hepatic decompensation.
7. Activity of novel ceftibuten-avibactam, ceftazidime-avibactam, and comparators against a challenge set of Enterobacterales from outpatient centers and nursing homes across the United States (2022-2024).
8. Impact of Initial Relative Dose Intensity on Tumor Response and Survival Outcomes in Enfortumab Vedotin Monotherapy for Previously Treated Advanced Urothelial Carcinoma: A Real-world Analysis From a Multicenter Study.
9. Utilizing large language models for gastroenterology research: a conceptual framework.
10. Toward a Bactericidal Oral Drug Combination for the Treatment of Mycobacterium abscessus Lung Disease.

CDAD

1. Functional diversification of dietary plant small molecules by the gut microbiome.
2. Treatment decision-making factors and sequencing in recurrent and/or metastatic squamous cell carcinoma of the head and neck.
3. Evaluation of Department of Defense hospital antimicrobial stewardship programs (ASPs) using a novel Core Elements scoring approach and modeling Core Elements scores with metrics related to ASP outcomes.
4. Non-invasive treatment of Clostridioides difficile infection with a human-origin probiotic cocktail through gut microbiome-gut metabolome modulations.
5. Anti-interleukin-23 treatment linked to improved Clostridioides difficile infection survival.
6. The effect of antibiotic prescription in non-critically ill hospitalized patients with COVID-19: A Japanese inpatient database study.
7. Genomic islands and molecular mechanisms relating to drug-resistance in Clostridioides (Clostridium) difficile PCR ribotype 176.
8. Associations Between Prophylactic IV Antibiotics and Outcomes in Patients With Acute Severe Brain Injury Who Require Mechanical Ventilation: Systematic Review and Meta-Analysis.
9. Full-length 16S rRNA sequencing revealed an altered microbiome diversity and composition of the jejunum and cecum in chicken infected with Eimeria necatrix.
10. Therapeutic activation of IL-22-producing innate lymphoid cells enhances host defenses to Clostridioides difficile infection.
11. Insights into gastrointestinal manifestation of human immunodeficiency virus: A narrative review.
12. The role of microbial succinate in the pathophysiology of inflammatory bowel disease: mechanisms and therapeutic potential.
13. The Impact of Endoscopic Healing on Disease-Related Outcomes in Patients With Ulcerative Proctitis.
14. Multifaceted challenges of deep venous thrombosis in the setting tetraplegia and ulcerative colitis: case report.
15. Pterostilbene attenuates intestinal barrier damage and secondary liver oxidative stress in a murine model of Clostridium difficile infection by regulating the gut microbiota.
16. Reducing femoral peri-implant fracture risk through optimized plate length and screw configuration - a biomechanical study.
17. Clostridioides difficile concentration-dependant alterations in gut microbiota of asymptomatic infants.

CMC

1. Research on the desalination kinetics of carbon tableting electrodes for capacitive deionization water purification.

Guidelines

1. Selective Ion Separation by Capacitive Deionization: A Comprehensive Review.
2. Epidemiologic profile of community-acquired Clostridioides difficile infections: a systematic review and meta-analysis.
3. Synergistic human health risks of microplastics and co-contaminants: A quantitative risk assessment in water.
4. Evaluation of Plasma Arginine Vasopressin During Hypertonic Saline Loading: A Comparison of Radioimmunoassay and Liquid Chromatography-Tandem Mass Spectrometry.
5. Mother-to-child transmission of hepatitis B in Far North Queensland, 2013-2023.
6. Vancomycin Population Pharmacokinetic Models in Non- Critically Ill Adults Patients: a scoping review.
7. [Fecal microbiota transplantation for the treatment of intestinal disorders: An analysis of treatment of 15 000 patients].
8. Effectiveness of Ampicillin-Sulbactam Versus Ceftriaxone for the Initial Treatment of Community-Acquired Pneumonia in Older Adults: A Target Trial Emulation Study.
9. Radiological Insights into Acellular Dermal Matrix Integration in Post-Mastectomy Breast Reconstruction: Implications for Cancer Patient Management.
10. Molecular Epidemiology of Clostridioides difficile Infections in Patients Hospitalized in 2017-2019 at the Central Teaching Hospital of Medical University of Lodz, Central Poland.
11. Comparison of B-mode, conventional color Doppler, and superb microvascular imaging for evaluating renal cortical thickness in dogs without and with chronic kidney disease.
12. Cone Beam-CT pulmonary angiography in balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: A review of technical parameters and benefits.
13. Adverse drug reactions linked to fidaxomicin: insights from a retrospective analysis of the FAERS database.
14. Mating from a female perspective: Do brown bear females play an active role in mate searching?
15. Fulminant Clostridioides difficile Infection: A Journey into the Unknown!

Non-toxigenic C. difficile

1. Clostridioides difficile in feral horse populations in Australia.
2. Environmental and Health Care Personnel Sampling and Unobserved Clostridium difficile Transmission in ICU.

MGB

Other news of possible interest